Fibrogen Inc CS (FGEN)

$9.71 +0.69 (7.65%)
Market Cap 39.28M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 36,202
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 97%
Beta 0.77
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 4 at 8:08 PM
$FGEN For me, what has fallen now is related to the external news background, not the company-related news. So it's all the same. As it has fallen, it will continue to grow. The most important thing is the results of the research and the decision of the FDA, the rest is not important.
1 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 4 at 7:09 PM
$FGEN Jesus Christ!!!!
1 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 10:16 AM
$FGEN Excellent article that nails exactly where FGEN stands right now. So if you want to update your FGEN knowledge or get acquainted with FGEN, this is a must read. https://everyticker.com/quote/FGEN/analysis/fibrogen-s-strategic-rebirth-unlocking-oncology-and-mds-potential-nasdaq-fgen
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 3 at 4:39 PM
$FGEN We are waiting for February 26. The results of testing FG-3246 in combination with enzalutamide in mCRPC will be presented at the ASCO GU conference. The ASCO GU Conference will be held on February 26-28, 2026 (Thursday–Saturday) at Moscone West, San Francisco, California.
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 2 at 10:39 AM
$FGEN Updated the KYNB news file (formerly ticker FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 2 at 9:28 AM
$FGEN Yes, there was a sale. I think the sell-off was on the background of geopolitical news. Plus the Chinese are playing with gold :) and silver. In general, a full bouquet. I think that the recent stock sell-off happened precisely because of this, and not because of some insiders and bad tests at KYNB (former ticker FGEN).
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 30 at 7:39 PM
$FGEN Market is bleeding too:
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 30 at 6:38 PM
$FGEN What’s actually going on with FGEN/KYNB (Q4 2025): No FDA approvals No PDUFA No Phase 3 data readout No IND acceptance announced The only “pending” thing for Q4 2025: A planned Phase 3 protocol submission for roxadustat in MDS → that’s paperwork, not a trial start, not approval, not a catalyst FG-3246 (oncology): Phase 2 ongoing Any Q4 2025 update = early combo data at best, nothing registrational Bottom line (plain English): Management talked up Q4 2025 Market expected something FDn’t moA hasved Stock stays dead because there is no real catalyst yet
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 29 at 9:04 PM
$FGEN $8 now, dmmmmmm
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 29 at 4:20 PM
$FGEN https://economictimes.indiatimes.com/news/international/us/us-stock-market-crashes-today-why-are-dow-sp-500-nasdaq-down-today-tesla-meta-microsoft-in-red/articleshow/127780471.cms?from=mdr
0 · Reply
Latest News on FGEN
No data available.
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 4 at 8:08 PM
$FGEN For me, what has fallen now is related to the external news background, not the company-related news. So it's all the same. As it has fallen, it will continue to grow. The most important thing is the results of the research and the decision of the FDA, the rest is not important.
1 · Reply
MaxMiamiFl
MaxMiamiFl Feb. 4 at 7:09 PM
$FGEN Jesus Christ!!!!
1 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 10:16 AM
$FGEN Excellent article that nails exactly where FGEN stands right now. So if you want to update your FGEN knowledge or get acquainted with FGEN, this is a must read. https://everyticker.com/quote/FGEN/analysis/fibrogen-s-strategic-rebirth-unlocking-oncology-and-mds-potential-nasdaq-fgen
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 3 at 4:39 PM
$FGEN We are waiting for February 26. The results of testing FG-3246 in combination with enzalutamide in mCRPC will be presented at the ASCO GU conference. The ASCO GU Conference will be held on February 26-28, 2026 (Thursday–Saturday) at Moscone West, San Francisco, California.
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 2 at 10:39 AM
$FGEN Updated the KYNB news file (formerly ticker FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Feb. 2 at 9:28 AM
$FGEN Yes, there was a sale. I think the sell-off was on the background of geopolitical news. Plus the Chinese are playing with gold :) and silver. In general, a full bouquet. I think that the recent stock sell-off happened precisely because of this, and not because of some insiders and bad tests at KYNB (former ticker FGEN).
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 30 at 7:39 PM
$FGEN Market is bleeding too:
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 30 at 6:38 PM
$FGEN What’s actually going on with FGEN/KYNB (Q4 2025): No FDA approvals No PDUFA No Phase 3 data readout No IND acceptance announced The only “pending” thing for Q4 2025: A planned Phase 3 protocol submission for roxadustat in MDS → that’s paperwork, not a trial start, not approval, not a catalyst FG-3246 (oncology): Phase 2 ongoing Any Q4 2025 update = early combo data at best, nothing registrational Bottom line (plain English): Management talked up Q4 2025 Market expected something FDn’t moA hasved Stock stays dead because there is no real catalyst yet
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 29 at 9:04 PM
$FGEN $8 now, dmmmmmm
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 29 at 4:20 PM
$FGEN https://economictimes.indiatimes.com/news/international/us/us-stock-market-crashes-today-why-are-dow-sp-500-nasdaq-down-today-tesla-meta-microsoft-in-red/articleshow/127780471.cms?from=mdr
0 · Reply
AceInTheHole18
AceInTheHole18 Jan. 29 at 1:20 PM
$FGEN we ripping to $20 anytime soon
3 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 27 at 4:36 PM
$FGEN this board has died. :( No news, no rumors, nothing but red
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 26 at 3:13 PM
$FGEN 4 new news. Updated the KYNB news file (formerly ticker FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
0 · Reply
mjtwins16
mjtwins16 Jan. 23 at 1:07 PM
$FGEN https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-4110/771898/Synergistic-treatment-of-prostate-cancer-and
0 · Reply
coolelel
coolelel Jan. 23 at 8:45 AM
$FGEN I'm sitting and writing this in the hospital. Someone very dear to me is next to me with stage 4 pancreatic cancer. Something that Pamrevlumab was supposed to help fix. The money I lost in this stock is nothing compared to the devastation that I and many others felt when we lost a potential drug candidate. I truly wish pamrevlumab succeeded.
2 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 21 at 6:51 AM
$FGEN updated the KYNB news file (formerly ticker FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 20 at 9:28 PM
$FGEN dmmmmmmm
2 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 19 at 2:19 PM
$FGEN No news about FDA . Should be soon. positive or negative
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 19 at 12:14 PM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41548783/
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jan. 17 at 7:17 AM
$FGEN links to news about KYNB (formerly FGEN) https://docs.google.com/spreadsheets/d/1cDIJN25xCpojie2eHDYLpphzN-PcizI_-TDIf0q7b9Q/edit?gid=0#gid=0
1 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 14 at 9:12 PM
$FGEN (BUY and HOLD) The trials compared 6 HIF-PHIs (roxadustat, daprodustat, vadadustat, molidustat, enarodustat, and desidustat) against erythropoiesis-stimulating agents (ESAs) or placebo. Treatment duration ranged from 4 to 104 weeks. Mean patient ranged from 48 to 72 years or older. For increasing hemoglobin levels, roxadustat ranked highest, particularly in the dialysis.
0 · Reply
MaxMiamiFl
MaxMiamiFl Jan. 14 at 9:00 PM
$FGEN let's go!!!
1 · Reply